Overview

Public BiotechPhase 1ketamine

CNS-focused biopharma with diverse portfolio including ADHD, Parkinson's, and depression treatments. Acquired Sage Therapeutics in 2025, adding ZURZUVAE for postpartum depression.

Visit Website

Rockville, MD

$2.8B
Market Cap
2005
Founded
0
Open Roles

Open Positions

No open positions at this time

Clinical Pipeline(1)

Completed·Phase 1·ketamine

Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants

SAGE-904Healthy Volunteer
NCT05049343